Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Search for other papers by Jennifer R. Brown in
Current site
Google Scholar
PubMed
The choice of therapy for chronic lymphocytic leukemia (newly diagnosed as well as relapsed/refractory disease) depends on the disease (presence or absence of del(17p) or TP53 mutation) and patient characteristics (age, comorbidities, functional status and patient preference). Many patients can choose between continuous treatment with a Bruton’s tyrosine kinase (BTK) inhibitor or time-limited therapy with venetoclax/obinutuzumab. For patients with 17p deletions, the data support the use of continuous treatment with a BTK inhibitor, although these patients should also be referred to clinical trials evaluating novel combination therapy options with minimal residual disease monitoring. The choice of therapy for relapsed disease also depends on prior therapy and duration of response to prior therapy in addition to the disease and patient characteristics (as mentioned earlier). BTK inhibitor– or venetoclax-based regimens are recommended for patients experiencing relapse following chemoimmunotherapy. In the case of disease relapse following BTK inhibitor therapy, prospective data are available only for venetoclax-based regimens, whereas disease relapse (after a period of durable remission) following time-limited therapy with venetoclax-based regimens can be managed through re-treatment with venetoclax or a BTK inhibitor.
Disclosures: Dr. Brown has disclosed receiving consulting fees from AbbVie, Inc., Acerta/Astra-Zeneca, BeiGene, Bristol-Myers Squibb/Juno/Celgene, Catapult, Eli Lilly and Company, Genentech/Roche, Janssen Pharmaceutica Products, LP, MEI Pharma Inc., MorphoSys AG, Nextcea, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Rigel; grant/research support from Gilead Sciences, Inc., Loxo/Lilly, SecuraBio, Sun, and TG Therapeutics; and other financial benefit from Invectys.
© 2019-2024 National Comprehensive Cancer Network